Maverick Capital Ltd. Grows Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Maverick Capital Ltd. boosted its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 36.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,600,524 shares of the company’s stock after buying an additional 691,894 shares during the quarter. SpringWorks Therapeutics accounts for approximately 1.9% of Maverick Capital Ltd.’s portfolio, making the stock its 18th largest holding. Maverick Capital Ltd. owned 3.50% of SpringWorks Therapeutics worth $97,962,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. grew its holdings in shares of SpringWorks Therapeutics by 16.9% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 758,712 shares of the company’s stock worth $28,581,000 after acquiring an additional 109,865 shares during the period. Duquesne Family Office LLC acquired a new stake in SpringWorks Therapeutics in the second quarter valued at $38,475,000. AQR Capital Management LLC increased its position in shares of SpringWorks Therapeutics by 92.9% in the second quarter. AQR Capital Management LLC now owns 37,413 shares of the company’s stock valued at $1,409,000 after buying an additional 18,017 shares in the last quarter. Magnetar Financial LLC acquired a new position in shares of SpringWorks Therapeutics during the 2nd quarter worth $502,000. Finally, Profund Advisors LLC boosted its position in shares of SpringWorks Therapeutics by 1.3% in the 2nd quarter. Profund Advisors LLC now owns 29,048 shares of the company’s stock worth $1,094,000 after buying an additional 362 shares in the last quarter.

SpringWorks Therapeutics Stock Performance

Shares of NASDAQ SWTX opened at $32.29 on Friday. The firm has a market cap of $2.40 billion, a P/E ratio of -6.28 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a 1 year low of $18.00 and a 1 year high of $53.92. The firm’s 50 day moving average price is $37.22 and its 200 day moving average price is $40.85.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.58. The business had revenue of $59.73 million for the quarter, compared to analyst estimates of $34.42 million. During the same quarter last year, the business earned ($1.25) EPS. SpringWorks Therapeutics’s revenue for the quarter was up 59732900.0% compared to the same quarter last year. As a group, equities analysts predict that SpringWorks Therapeutics, Inc. will post -3.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on SWTX shares. HC Wainwright restated a “buy” rating and set a $76.00 target price on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. JPMorgan Chase & Co. upped their target price on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Finally, Wedbush reissued an “outperform” rating and set a $77.00 price target (up previously from $75.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics has a consensus rating of “Buy” and an average price target of $68.50.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.